Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC and Reduced Intensity HCT for High-Risk Sickle Cell and RBC Disorders
NCT00957931Phase 2Completed
- Sponsor
- Stanford University
- Start
- Mar 2009
- Primary completion
- Aug 2013
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Provacel in sickle cell disease (SCD), thalassemia, Diamond-Blackfan anemia (DBA), sponsored by Stanford University. Started Mar 2009; status: completed.
02
Drugs
Provacel
03
Conditions
sickle cell disease (SCD)thalassemiaDiamond-Blackfan anemia (DBA)
Beyond the preview
Go deeper on NCT00957931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00957931.